Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Comparison 1 One topical agent versus placebo, Outcome 1 Eradication of MRSA from all sites.
Figuras y tablas -
Analysis 1.1

Comparison 1 One topical agent versus placebo, Outcome 1 Eradication of MRSA from all sites.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 One topical agent versus placebo, Outcome 2 Nasal MRSA eradication.
Figuras y tablas -
Analysis 1.2

Comparison 1 One topical agent versus placebo, Outcome 2 Nasal MRSA eradication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 One topical agent versus placebo, Outcome 3 MRSA infection.
Figuras y tablas -
Analysis 1.3

Comparison 1 One topical agent versus placebo, Outcome 3 MRSA infection.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 One systemic agent versus no treatment, Outcome 1 Eradication of MRSA from all sites (day 30).
Figuras y tablas -
Analysis 2.1

Comparison 2 One systemic agent versus no treatment, Outcome 1 Eradication of MRSA from all sites (day 30).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 One systemic agent versus no treatment, Outcome 2 Eradication of MRSA from all sites (day 90).
Figuras y tablas -
Analysis 2.2

Comparison 2 One systemic agent versus no treatment, Outcome 2 Eradication of MRSA from all sites (day 90).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Two systemic agents versus no treatment, Outcome 1 Eradication of MRSA from all sites (day 30).
Figuras y tablas -
Analysis 3.1

Comparison 3 Two systemic agents versus no treatment, Outcome 1 Eradication of MRSA from all sites (day 30).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Two systemic agents versus no treatment, Outcome 2 Eradication of MRSA from all sites (day 90).
Figuras y tablas -
Analysis 3.2

Comparison 3 Two systemic agents versus no treatment, Outcome 2 Eradication of MRSA from all sites (day 90).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 One topical versus one topical and one systemic agent, Outcome 1 Eradication of nasal MRSA.
Figuras y tablas -
Analysis 4.1

Comparison 4 One topical versus one topical and one systemic agent, Outcome 1 Eradication of nasal MRSA.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 One systemic agent versus one systemic agent, Outcome 1 Eradication of MRSA from all sites (day 30).
Figuras y tablas -
Analysis 5.1

Comparison 5 One systemic agent versus one systemic agent, Outcome 1 Eradication of MRSA from all sites (day 30).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 One systemic agent versus one systemic agent, Outcome 2 Eradication of MRSA from all sites (day 90).
Figuras y tablas -
Analysis 5.2

Comparison 5 One systemic agent versus one systemic agent, Outcome 2 Eradication of MRSA from all sites (day 90).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Two systemic agents versus one systemic agent, Outcome 1 Eradication of MRSA from all sites (day 30).
Figuras y tablas -
Analysis 6.1

Comparison 6 Two systemic agents versus one systemic agent, Outcome 1 Eradication of MRSA from all sites (day 30).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Two systemic agents versus one systemic agent, Outcome 2 Eradication of MRSA from all sites (day 90).
Figuras y tablas -
Analysis 6.2

Comparison 6 Two systemic agents versus one systemic agent, Outcome 2 Eradication of MRSA from all sites (day 90).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Two systemic agents versus one systemic agent, Outcome 3 Eradication of MRSA from all sites (day 14).
Figuras y tablas -
Analysis 6.3

Comparison 6 Two systemic agents versus one systemic agent, Outcome 3 Eradication of MRSA from all sites (day 14).

Ir a la figura de la revisiónAbrir en una pestaña nueva
Table 1. Detailed search strategy for MEDLINE and EMBASE

Search number

MEDLINE (on OVID)

EMBASE (on OVID)

(1)

Staphylococcal infections/

Staphylococcal infection/

(2)

Staphylococcal skin infections/

Staphylococcus aureus/

(3)

Staphylococcus aureus/

Staphylococcus aureus[tw]

(4)

Staphylococcus aureus[tw]

Methicillin resistant Staphylococcus aureus/

(5)

Methicillin resistance/

methicillin‐resistant staphylococcus aureus[tw]

(6)

Methicillin resistance ointments/

methicillin resistant staphylococcus aureus[tw]

(7)

methicillin‐resistant staphylococcus aureus[tw]

MRSA[tw]

(8)

methicillin resistant staphylococcus aureus[tw]

1or 2 or 3 or 4 or 5 or 6 or 7

(9)

MRSA[tw]

limit 8 to human

(10)

1or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9

(11)

limit 10 to human

/ = MeSH term; tw = text word

/ = EMTREE term; tw = text word
Figuras y tablas -
Table 1. Detailed search strategy for MEDLINE and EMBASE
Ir a la tabla de la revisión
Table 2. Methodological quality of included studies

Study

Allocation sequence

Concealment

Blinding

Follow up

Harbath 1999

Unclear

Unclear

Met

Met

Chang 2000

Unclear

Unclear

Unclear

Not met

Parras 1995

Met

Unclear

Unclear

Not met

Muder 1994

Unclear

Unclear

Unclear

Met

Walsh 1993

Met

Met

Met

Not met

Peterson 1990

Unclear

Unclear

Unclear

Met
Figuras y tablas -
Table 2. Methodological quality of included studies
Ir a la tabla de la revisión
Comparison 1. One topical agent versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Eradication of MRSA from all sites Show forest plot

1

98

Risk Ratio (M‐H, Fixed, 95% CI)

1.39 [0.64, 2.99]

1.1 Mupirocin

1

98

Risk Ratio (M‐H, Fixed, 95% CI)

1.39 [0.64, 2.99]

2 Nasal MRSA eradication Show forest plot

1

87

Risk Ratio (M‐H, Fixed, 95% CI)

1.77 [0.96, 3.26]

3 MRSA infection Show forest plot

1

96

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.13, 1.70]
Figuras y tablas -
Comparison 1. One topical agent versus placebo
Ir a la tabla de la revisión
Comparison 2. One systemic agent versus no treatment

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Eradication of MRSA from all sites (day 30) Show forest plot

2

41

Risk Ratio (M‐H, Fixed, 95% CI)

1.83 [0.60, 5.56]

1.1 Fusidic acid

1

16

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.18, 2.42]

1.2 Rifampin/minocycline

1

25

Risk Ratio (M‐H, Fixed, 95% CI)

8.0 [0.53, 121.59]

2 Eradication of MRSA from all sites (day 90) Show forest plot

2

41

Risk Ratio (M‐H, Fixed, 95% CI)

1.56 [0.56, 4.32]

2.1 Fusidic acid

1

16

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.18, 2.42]

2.2 Rifampin/minocycline

1

25

Risk Ratio (M‐H, Fixed, 95% CI)

3.89 [0.60, 25.01]
Figuras y tablas -
Comparison 2. One systemic agent versus no treatment
Ir a la tabla de la revisión
Comparison 3. Two systemic agents versus no treatment

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Eradication of MRSA from all sites (day 30) Show forest plot

1

17

Risk Ratio (M‐H, Fixed, 95% CI)

9.45 [0.62, 144.74]

1.1 Rifampin and minocycline

1

17

Risk Ratio (M‐H, Fixed, 95% CI)

9.45 [0.62, 144.74]

2 Eradication of MRSA from all sites (day 90) Show forest plot

1

17

Risk Ratio (M‐H, Fixed, 95% CI)

3.50 [0.51, 23.81]

2.1 Rifampin and minocycline

1

17

Risk Ratio (M‐H, Fixed, 95% CI)

3.50 [0.51, 23.81]
Figuras y tablas -
Comparison 3. Two systemic agents versus no treatment
Ir a la tabla de la revisión
Comparison 4. One topical versus one topical and one systemic agent

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Eradication of nasal MRSA Show forest plot

1

182

Risk Ratio (M‐H, Fixed, 95% CI)

1.05 [0.97, 1.14]

1.1 Day 14

1

67

Risk Ratio (M‐H, Fixed, 95% CI)

1.04 [0.93, 1.15]

1.2 Day 21

1

51

Risk Ratio (M‐H, Fixed, 95% CI)

1.09 [0.95, 1.26]

1.3 Day 28

1

43

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.88, 1.16]

1.4 Day 90

1

21

Risk Ratio (M‐H, Fixed, 95% CI)

1.1 [0.64, 1.89]
Figuras y tablas -
Comparison 4. One topical versus one topical and one systemic agent
Ir a la tabla de la revisión
Comparison 5. One systemic agent versus one systemic agent

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Eradication of MRSA from all sites (day 30) Show forest plot

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

0.16 [0.02, 1.00]

1.1 Minocycline versus rifampin

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

0.16 [0.02, 1.00]

2 Eradication of MRSA from all sites (day 90) Show forest plot

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

0.54 [0.20, 1.43]

2.1 Minocycline versus rifampin

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

0.54 [0.20, 1.43]
Figuras y tablas -
Comparison 5. One systemic agent versus one systemic agent
Ir a la tabla de la revisión
Comparison 6. Two systemic agents versus one systemic agent

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Eradication of MRSA from all sites (day 30) Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

1.2 [0.60, 2.38]

1.1 Rifampin and minocycline versus combined rifampin and minocycline

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

1.2 [0.60, 2.38]

2 Eradication of MRSA from all sites (day 90) Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.9 [0.43, 1.90]

2.1 Rifampin and minocycline or ciprofloxacin and rifampin versus combination

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.9 [0.43, 1.90]

3 Eradication of MRSA from all sites (day 14) Show forest plot

2

115

Risk Ratio (M‐H, Fixed, 95% CI)

1.16 [0.85, 1.60]

3.1 Ciprofloxicin and rifampin versus trimethoprim‐sulfamethoxazole

1

21

Risk Ratio (M‐H, Fixed, 95% CI)

0.73 [0.27, 1.97]

3.2 Novobiacin and rifampin versus trimethoprim‐sulfamethoxazole

1

94

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [0.90, 1.76]
Figuras y tablas -
Comparison 6. Two systemic agents versus one systemic agent
Ir a la tabla de la revisión